|
AI is reshaping healthcare fast. Below are 3 key AI developments, 2 studies, and 1 takeaway to help you better lead with AI. Target read time: 5 minutes.
|
Days after launching ChatGPT Health, OpenAI acquired Torch—a 4-person startup building a "unified medical memory" to consolidate scattered health data from doctor visits, lab tests, and wearables into one place. The deal is valued at $60-100M. Torch's team came from Forward Health, which raised over $400M before shutting down in late 2024.
So what?
OpenAI isn't just building a health chatbot—it's assembling the infrastructure to unify fragmented patient data. The real play: becoming the connective tissue between your medical records and AI.
Read the full story →
Anthropic announced Claude for Healthcare—HIPAA-ready tools for providers, payers, and patients—on the same day as OpenAI's Torch acquisition. The platform connects to the CMS Coverage Database, ICD-10, NPI Registry, and PubMed. New "agent skills" target prior authorization and FHIR development. Partners include AstraZeneca, Sanofi, Banner Health, and Flatiron.
So what?
Two foundation model companies launched healthcare products on the same day. Google, Meta and others can't be far behind. Foundation model competition has officially arrived in healthcare.
Read the full story →
Hippocratic AI, which builds patient-facing AI agents, acquired Grove AI to form a new life sciences division. Grove has powered 50+ phase 2/3 clinical trials and more than 10 million patient interactions.
So what?
Healthcare AI is consolidating through M&A. Startups developing narrow, well-formulated end-to-end use cases (with traction) are compelling targets for inorganic growth for larger players.
Read the full story →
|
The State of Clinical AI (2026) report from Stanford and Harvard researchers found that AI systems excel at prediction tasks but struggle with incomplete information and clinical uncertainty—the reality of everyday medicine. Nearly half of medical AI studies use exam-style questions rather than real patient data, creating a disconnect between how systems are tested and how they function in practice.
Why it matters
The gap between controlled research and messy clinical reality remains wide. AI works best when augmenting clinicians, not replacing them.
Read the report →
Digital health startups raised $14.2B in 2025—the highest since 2022. AI-focused companies captured 54% of total funding (up from 37% in 2024) and commanded a 19% premium on deal sizes. Mega-rounds exceeding $100M accounted for 42% of all funding. Five companies broke the three-year IPO drought (Hinge Health, Omada Health, Heartflow, Carlsmed, Profusa).
Why it matters
Capital is concentrating in fewer, larger AI bets. The "murky middle" is getting squeezed—scale or struggle.
Read the report →
|
AI struggles in the real-world of medicine.
This week's Stanford-Harvard report surfaced an uncomfortable truth: nearly half of medical AI studies don't use real patient data. Instead, they test on exam-style questions—clean, complete, unambiguous. The real world is none of those things. Case in point: Just adding a "None of the other answers" option dropped AI accuracy in some cases by more than 1/3 (Bedi et al., JAMA, 2025).
The finding explains a persistent gap. AI systems that match or beat physicians on structured tests often falter when facing incomplete information, clinical uncertainty, and the messy context of actual patient care. The report's verdict: AI works best when augmenting clinicians, not replacing them.
Meanwhile, $14.2 billion in funding is chasing healthcare AI—with 54% going to AI-focused companies and mega-rounds dominating. The market is betting big on a small number of scaled platforms. But the Stanford-Harvard findings suggest many of these bets are being placed before the evidence catches up.
Takeaway
For health system and plan leaders evaluating AI vendors: ask how they've validated performance. If the answer is benchmarks and board exams—not real clinical workflows with real patients—the impressive demo may not translate to your environment. Real-world validation (in the messy world of clinical medicine) will be what ultimately separates hype from reality.
|
|